Brief: Shenzhen Hepalink Pharmaceutical Announces FY Loss Attributable Of RMB783.3 Mln
March 28 (Reuters) - Shenzhen Hepalink Pharmaceutical
Group Co Ltd 002399.SZ :
* FY LOSS ATTRIBUTABLE RMB783.3 MILLION VERSUS PROFIT
RMB727.4
MILLION
* FY REVENUE RMB5,431.0 MILLION VERSUS RMB7,151.0 MILLION
Further company coverage: 002399.SZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shenzhen Hepalink Pharmaceutical Co
See all newsBrief: Shenzhen Hepalink Pharmaceutical Group Says Enoxaparin Sodium Injection Obtains New Manufacturer Authorization From EMA
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB156.6 Million
Brief: Shenzhen Hepalink Pharmaceutical Posts Profit Attributable RMB646.7 Million For Year
Brief: Shenzhen Hepalink Pharmaceutical Says Enoparin Approved In Argentina
Brief: Shenzhen Hepalink Pharmaceutical Says H1710 Injection Received Approval For From NMPA